Hinge Health (NYSE:HNGE) Downgraded to Buy Rating by Wall Street Zen

Hinge Health (NYSE:HNGE) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also recently issued research reports about the stock. Evercore reissued an “outperform” rating and set a $45.00 target price on shares of Hinge Health in a report on Wednesday, April 8th. KeyCorp set a $55.00 target price on shares of Hinge Health in a report on Wednesday, February 11th. Stifel Nicolaus raised their target price on shares of Hinge Health from $59.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Canaccord Genuity Group raised their target price on shares of Hinge Health from $63.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective on shares of Hinge Health in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $67.53.

Hinge Health Price Performance

Shares of Hinge Health stock opened at $63.48 on Friday. The firm has a fifty day moving average price of $47.93 and a 200 day moving average price of $45.31. Hinge Health has a 1 year low of $30.08 and a 1 year high of $66.55. The stock has a market cap of $4.91 billion and a PE ratio of -5.14.

Hinge Health (NYSE:HNGE) last issued its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.33. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The firm had revenue of $182.31 million during the quarter. During the same period last year, the business earned $1.30 EPS. The company’s revenue for the quarter was up 47.2% on a year-over-year basis. As a group, equities analysts expect that Hinge Health will post 1.21 EPS for the current year.

Insider Buying and Selling at Hinge Health

In other Hinge Health news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of Hinge Health stock in a transaction on Monday, June 1st. The shares were sold at an average price of $60.22, for a total value of $5,018,373.48. Following the completion of the transaction, the chairman owned 83,334 shares of the company’s stock, valued at approximately $5,018,373.48. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Antonio Perez sold 104,544 shares of Hinge Health stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $55.09, for a total transaction of $5,759,328.96. Following the completion of the transaction, the chief executive officer directly owned 35,470 shares of the company’s stock, valued at $1,954,042.30. The trade was a 74.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 554,600 shares of company stock valued at $29,859,068. Corporate insiders own 18.92% of the company’s stock.

Institutional Trading of Hinge Health

A number of institutional investors and hedge funds have recently modified their holdings of HNGE. BIT Capital GmbH increased its stake in shares of Hinge Health by 79.3% during the fourth quarter. BIT Capital GmbH now owns 3,316,101 shares of the company’s stock worth $154,033,000 after purchasing an additional 1,466,577 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Hinge Health by 110.5% during the fourth quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company’s stock worth $121,027,000 after purchasing an additional 1,367,693 shares in the last quarter. Tiger Global Management LLC increased its stake in shares of Hinge Health by 227.1% during the fourth quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company’s stock worth $83,877,000 after purchasing an additional 1,253,743 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Hinge Health during the fourth quarter worth about $54,469,000. Finally, Millennium Management LLC increased its stake in shares of Hinge Health by 225.0% during the fourth quarter. Millennium Management LLC now owns 1,479,642 shares of the company’s stock worth $68,729,000 after purchasing an additional 1,024,317 shares in the last quarter.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Hinge Health to $65 from $63 and reiterated a buy rating, reinforcing a constructive analyst view on the stock. Article Title
• Positive Sentiment: Other recent commentary also stayed upbeat, including technical coverage pointing to a “golden cross,” which can attract momentum investors. Article Title
• Positive Sentiment: Hinge Health’s last earnings report beat estimates, with revenue up 47.2% year over year, supporting the view that the business is still growing rapidly. Article Title
• Neutral Sentiment: One article highlighted Hinge Health as a promising mid-cap healthcare name, but it did not include a new catalyst beyond a generally favorable long-term investment case. Article Title
• Negative Sentiment: Chairman Gabriel M.I. Mecklenburg disclosed another large insider sale of 50,000 shares at $65.54, adding to a series of recent sales and potentially creating some overhang for sentiment. Article Title

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.